NO955189D0 - En forkortet keratinocyt vekstfaktor (KGF) med ökende biologisk aktivitet - Google Patents

En forkortet keratinocyt vekstfaktor (KGF) med ökende biologisk aktivitet

Info

Publication number
NO955189D0
NO955189D0 NO955189A NO955189A NO955189D0 NO 955189 D0 NO955189 D0 NO 955189D0 NO 955189 A NO955189 A NO 955189A NO 955189 A NO955189 A NO 955189A NO 955189 D0 NO955189 D0 NO 955189D0
Authority
NO
Norway
Prior art keywords
kgf
abbreviated
keratinocyte growth
growth factor
biological activity
Prior art date
Application number
NO955189A
Other languages
English (en)
Norwegian (no)
Other versions
NO955189L (no
Inventor
Denis Gospodarowicz
Frank Masiarz
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of NO955189D0 publication Critical patent/NO955189D0/no
Publication of NO955189L publication Critical patent/NO955189L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO955189A 1993-06-29 1995-12-20 En forkortet keratinocyt vekstfaktor (KGF) med ökende biologisk aktivitet NO955189L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8642793A 1993-06-29 1993-06-29
PCT/US1994/004694 WO1995001434A1 (en) 1993-06-29 1994-04-28 A truncated keratinocyte growth factor (kgf) having increased biological activity

Publications (2)

Publication Number Publication Date
NO955189D0 true NO955189D0 (no) 1995-12-20
NO955189L NO955189L (no) 1995-12-20

Family

ID=22198501

Family Applications (1)

Application Number Title Priority Date Filing Date
NO955189A NO955189L (no) 1993-06-29 1995-12-20 En forkortet keratinocyt vekstfaktor (KGF) med ökende biologisk aktivitet

Country Status (25)

Country Link
US (7) US5677278A (de)
EP (2) EP1493812A3 (de)
JP (4) JP3570516B2 (de)
KR (1) KR960703433A (de)
CN (1) CN1129955A (de)
AT (1) ATE278777T1 (de)
AU (1) AU681405B2 (de)
BG (1) BG100236A (de)
BR (1) BR9407035A (de)
CA (1) CA2166278A1 (de)
CZ (1) CZ343795A3 (de)
DE (2) DE122006000005I2 (de)
DK (1) DK0706563T3 (de)
ES (1) ES2227527T3 (de)
FI (1) FI956203A (de)
FR (1) FR06C0004I2 (de)
HU (1) HUT73453A (de)
LU (1) LU91215I2 (de)
NL (1) NL300217I2 (de)
NO (1) NO955189L (de)
NZ (1) NZ266622A (de)
PL (1) PL312257A1 (de)
PT (1) PT706563E (de)
SK (1) SK153295A3 (de)
WO (1) WO1995001434A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026291B1 (en) 1989-01-31 2006-04-11 The United States Of America As Represented By The Department Of Health And Human Services Epithelial cell specific growth factor, keratinocyte growth factor (KGF)
GEP20022681B (en) * 1989-01-31 2002-04-25 Aaronson Us Stuart A Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth
US5965530A (en) * 1993-03-26 1999-10-12 Amgen Inc. Therapeutic uses of keratinocyte growth factor
US7084119B2 (en) * 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
JP3570516B2 (ja) * 1993-06-29 2004-09-29 カイロン コーポレイション 増加した生物学的活性を有する短縮型ケラチノサイト増殖因子(kgf)
WO1996011950A1 (en) * 1994-10-13 1996-04-25 Amgen Inc. Method of treating diabetes mellitus using kgf
PT785949E (pt) * 1994-10-13 2003-09-30 Amgen Inc Metodo para purificar factores de crescimento de queratinocitos
US6008328A (en) * 1994-10-13 1999-12-28 Amgen Inc. Method for purifying keratinocyte growth factors
AU745815B2 (en) * 1994-10-13 2002-04-11 Biovitrum Ab (Publ) Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6077692A (en) * 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
ES2293137T3 (es) * 1995-10-11 2008-03-16 Novartis Vaccines And Diagnostics, Inc. Combinacion de pdgf, kgf,igf e igfbp para curacion de heridas.
US6692961B1 (en) 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
SI0935652T1 (en) * 1996-10-15 2004-06-30 Amgen Inc. Keratinocyte growth factor-2 products
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
GB2322132B (en) * 1996-10-15 1999-09-22 Amgen Inc Keratinocyte growth factor-2 products
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
CA2294569A1 (en) * 1997-06-19 1998-12-23 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US20080233086A1 (en) * 1997-09-05 2008-09-25 Canbiocin Inc. Expression Vectors for Treating Bacterial Infections
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
NZ505324A (en) 1997-12-22 2002-11-26 Human Genome Sciences Inc Liquid and lyophilised KGF-2 polypeptide formulations used to accelerate soft tissue growth or regeneration
KR20010040906A (ko) * 1998-02-13 2001-05-15 휴먼 게놈 사이언시즈, 인크. 각질세포 성장 인자-2의 치료학적 용도
DE19934510B4 (de) * 1999-07-22 2009-04-16 Vermicon Ag Verfahren zum Nachweis von Mikroorganismen
WO2001027301A2 (en) 1999-10-15 2001-04-19 The Rockefeller University System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae
DE10024334B4 (de) * 2000-05-17 2006-06-01 Medigene Ag Verfahren zum Einbringen von Nukleinsäure in eine Zelle (Transfektion) mittels Calciumphosphat
EP1414866A2 (de) 2000-11-21 2004-05-06 The Texas A & M University System Fgf-affinitätschromatographie
US20030186904A1 (en) * 2001-01-08 2003-10-02 Human Genome Sciences, Inc. Keratinocyte growth factor-2
CA2438652A1 (en) 2001-02-19 2002-09-06 Merck Patent Gesellschaft Mit Beschraenkter Haftung Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
WO2003016505A2 (en) * 2001-08-21 2003-02-27 Chiron Corporation Kgf polypeptide compositions
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
PL1827483T3 (pl) * 2004-12-15 2014-12-31 Swedish Orphan Biovitrum Ab Publ Formulacje terapeutyczne czynnika wzrostu keratynocytów
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
CA2630220C (en) * 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
GB0611405D0 (en) * 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
KR101021197B1 (ko) * 2008-04-11 2011-03-11 (주)케어젠 성장인자―미미킹 펩타이드 및 그의 용도
EP2454368A4 (de) 2009-07-17 2013-01-09 Aaron Thomas Tabor Zusammensetzungen und verfahren zur genetischen modifizierung von zellen mit kosmetischer funktion zur verbesserung des kosmetischen erscheinungsbilds
KR20160083884A (ko) 2013-11-01 2016-07-12 스페리움 바이오메드 에스.엘. 치료제 및 미용제의 경피 전달을 위한 봉입체
CN117858717A (zh) 2021-08-30 2024-04-09 联合化学实验室有限公司 用于治疗炎症性疾病的蛋白质组合物
KR20230070596A (ko) * 2021-11-15 2023-05-23 (주)피앤피바이오팜 안정성이 증가된 인간 각질세포 성장인자1 변이체 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20022681B (en) * 1989-01-31 2002-04-25 Aaronson Us Stuart A Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5965530A (en) 1993-03-26 1999-10-12 Amgen Inc. Therapeutic uses of keratinocyte growth factor
JP3570516B2 (ja) 1993-06-29 2004-09-29 カイロン コーポレイション 増加した生物学的活性を有する短縮型ケラチノサイト増殖因子(kgf)
DK0785950T3 (da) 1994-10-13 2003-07-28 Amgen Inc Keratinocyt vækstfaktoranaloger
WO1996011950A1 (en) 1994-10-13 1996-04-25 Amgen Inc. Method of treating diabetes mellitus using kgf

Also Published As

Publication number Publication date
JP2004166709A (ja) 2004-06-17
DE122006000005I2 (de) 2006-11-23
AU6820894A (en) 1995-01-24
ATE278777T1 (de) 2004-10-15
EP1493812A3 (de) 2006-02-08
HU9503857D0 (en) 1996-02-28
JP2006075173A (ja) 2006-03-23
HUT73453A (en) 1996-08-28
DE69434053D1 (de) 2005-01-20
SK153295A3 (en) 1996-11-06
PT706563E (pt) 2005-01-31
NZ266622A (en) 1997-10-24
JP4662569B2 (ja) 2011-03-30
US5843883A (en) 1998-12-01
NL300217I2 (nl) 2006-05-01
US20090093400A1 (en) 2009-04-09
LU91215I2 (en) 2006-03-27
US5773586A (en) 1998-06-30
US5863767A (en) 1999-01-26
FR06C0004I1 (de) 2006-03-10
PL312257A1 (en) 1996-04-01
ES2227527T3 (es) 2005-04-01
FI956203A0 (fi) 1995-12-22
US5677278A (en) 1997-10-14
US6074848A (en) 2000-06-13
EP1493812A2 (de) 2005-01-05
DE69434053T2 (de) 2006-02-23
CZ343795A3 (en) 1996-07-17
EP0706563B1 (de) 2004-10-06
NL300217I1 (nl) 2006-04-03
CN1129955A (zh) 1996-08-28
JP3570516B2 (ja) 2004-09-29
JPH09500267A (ja) 1997-01-14
KR960703433A (ko) 1996-08-17
FI956203A (fi) 1996-02-07
BG100236A (en) 1996-07-31
US6677301B1 (en) 2004-01-13
DE122006000005I1 (de) 2006-08-10
NO955189L (no) 1995-12-20
FR06C0004I2 (fr) 2006-12-29
WO1995001434A1 (en) 1995-01-12
JP2009062396A (ja) 2009-03-26
CA2166278A1 (en) 1995-01-12
BR9407035A (pt) 1996-03-12
EP0706563A1 (de) 1996-04-17
DK0706563T3 (da) 2005-01-31
AU681405B2 (en) 1997-08-28

Similar Documents

Publication Publication Date Title
NO955189D0 (no) En forkortet keratinocyt vekstfaktor (KGF) med ökende biologisk aktivitet
ATE295414T1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
ATE139569T1 (de) Modifizierter, menschlicher gewebeplasminogenaktivator und seine herstellung
DE69024862D1 (de) Modifiziertes, biologisch aktives Protein
ES2184728T3 (es) Proteinas de union a la fibronectina.
DE69024104D1 (de) Polypeptide und Polypeptidanaloge mit inhibitorischer Aktivität gegenüber menschlicher Elastase
DE69126049T2 (de) Vektoren und Zusammensetzungen zur Expression von Glykosilationsmutanten des menschlichen Proteins-C
DE69225597D1 (de) Peptide mit einer lanthionin-brücke
DE59409964D1 (de) Rekombinante D-Hydantoinase, Verfahren zur Herstellung und Verwendung
DE69433238D1 (de) Pflanzenpromoter, microorganismen und pflanzenzellen mit einer expressionseinheit für ein gewünschtes protein, das besagten promoter enthält
PT90504A (pt) Processo para a preparacao de alcoois peptidicos com actividade anticoagulante
ATE145939T1 (de) Mitogen für die glatte muskulatur und dessen kodierende dns
IT1231764B (it) Composizione poliuretanica con capacita' di assorbire umidita', particolarmente adatta per la fabbricazione di cuoio sintetico e simili, e procedimento per la sua produzione.
EP0206329A3 (en) Sprung floor
DE69529405T2 (de) Pd-ecgf / thymidin phosphorylase spezifischer monoklonaler antikörper
DE69504220T2 (de) Sulfonamidodioxepane mit hypoglykämischen Eigenschaften, Methoden zu ihrer Herstellung, ihre Zwischenprodukte und Salze
ATE290598T1 (de) Neue staphylokinase derivate
ES2053474T3 (es) 1,2,3-tiadazol-4-tiolatos substituidos.